The lesson of this year's BIO International Convention in San Diego is not that the market has finally discovered the Unified Patent Court; it has been aware of it for some time. It is that life…
This week, I have the pleasure of speaking in Amsterdam at C5’s 19th Annual Forum on Pharma & Biotech Patent Litigation in Europe, in a panel devoted to running and defending preliminary injunctions…
Matthieu Dhenne and Marco Stief recently published on this blog two articles on the subject of the 'first marketing authorization' under Article 3(d) of Regulation (EC) No 469/2009, aka the SPC…
This second contribution completes the analysis developed in Part 1. Building on the product-centred reasoning adopted by the District Court of The Hague, it examines the limits of that approach in…
I am particularly pleased to publish this commentary, co-authored with my friend and colleague Marco Stief, whose earlier work on this decision provided the starting point for the present analysis,…
Two years after its launch, the Unified Patent Court has moved from promise to practice. What once looked like a procedural experiment has become a credible, fast, and intellectually rigorous forum…
In Du Hast, But Not So Fast, I suggested that the apparent hegemony of a few UPC divisions would in time recede under the pressure of practice and appellate calibration. The plot seems to be moving…
In 1976, Tom Scholz—a MIT-trained engineer and sonic perfectionist—spent months layering guitar tracks in the basement of his Boston apartment to produce More Than a Feeling, a song whose depth came…
Although the equation A + B = C seems self-evident (even for a five years old boy: remember you), the fact remains that it needed clarification by the Court of Justice of the European Union ("CJEU"),…